Mensagem


8th Medinterna International Meeting - “Systemic Autoimmune Diseases Revisited”

20th, 21st, 22nd And 23rd January 2010
Ipanema Park Hotel, Porto


Dear Colleague,

The 8th Medinterna Annual Meeting Autoimmune Diseases will take place on the 20th, 21st, 22nd and 23rd January 2010 at Ipanema Park Hotel (Porto). This edition’s subject will be Autoimmune Diseases Revisited.

Our special aim is to promote and support Internal Medicine studies, mainly for young internists and residents.

Autoimmune diseases greatest challenges are diagnostic abilities and therapeutic strategies. Internal Medicine is considered the most accomplished speciality to study their multissistemic and multidisciplinary achievement, often needing immediate and complex decisions. There are several controversial situations that lead to opposite positions on issues, like new trials on SLEtherapy, SLE and pregnancy, SLE and APS, Sarcoidosis, Sjögren´s syndrome, ANCA vasculitis, Systemic Sclerosis, the controversial use of Biologic Therapy, antiagregation and hypocoagulation on APS, the use of statins in SLE, among other situations. All this will be revisited at 8th Medinterna Meeting on Autoimmune Diseases.

The scientific program consists on discussions of case reports, round tables, lectures and cutting edge debates, combining speakers from Spain, United Kingdom, Israel, Netherlands, Italy, France, Gremany and Greece, as well as portuguese of undeniable reputation. As a novelty, an expert will do a summary of the most important issues discussed on each part of the meeting, and a final conclusion.

We do hope that all scientific talks will be interesting and useful for clinical practice. All internists, rheumatologists, clinical pathologists and immunologists, specialy young internists and residents are invited to scientific sessions.

We hope to see you all soon,

Carlos Dias

Major Sponsors

actelion bayer roche servier

Gold Sponsors

boehringer glaxo merck

Silver Sponsors

abbot astrazeneca cslbehring leo-pharma menarini octapharma omtapharma pfizer phadia sanofi